BMI and Odds of Endometrial Adenocarcinoma in Czech Women – a Case Control Study
Authors:
Michal Tichý 1,2; Hana Ptáčková 1; Dominika Plančíková 3; Marek Majdan 3; Martina Chodacká 4
Authors place of work:
Gastroenterologické oddělení, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z.
1; Nutriční ambulance, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z.
2; Katedra verejného zdravotníctva, Fakulta zdravotníctva a sociálnej práce, Trnavská univerzita v Trnave
3; Onkologické oddělení, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z.
4
Published in the journal:
Klin Onkol 2019; 32(4): 281-287
Category:
Original Articles
doi:
https://doi.org/10.14735/amko2019281
Summary
Introduction: The incidence of malignant tumors of the uterine body is increasing in the Czech Republic. Endometrial adenocarcinoma is one of the most frequent morphological types. Obesity or even overweight is a risk factor for the development of this disease. More accurate stratification of risk relative to body mass index (BMI) has not yet been determined in the Czech Republic, although the risk of overweight (BMI 25–29.9) has been reported in one study as comparable to that of first or second degree obesity (BMI 30–30.9).
Patients and methods: The study population included 376 women of Caucasian race diagnosed with endometrial adenocarcinoma, with BMI measured simultaneously, in 2005–2017. A control group consisted of an equal number of age-matched women not diagnosed with any oncological or gynecological disease. These two files were statistically processed.
Results: Odds (OR, 95% CI) relative to normal weight women, overweight women were at 2.26-times higher odds of endometrial adenocarcinoma, and women with obesity were at 5.18-8.67-, and 24.70-times higher odds, depending on the severity of obesity.
Conclusion: The hypothesis that overweight represents same risk for the development of endometrial adenocarcinoma, as lower degrees of obesity was not verified. However overweight is serious risk for endometrial adenocarcinoma development. The odds of endometrial adenocarcinoma is correlated with increasing BMI and in the population studied is higher than reported previously for all endometrial carcinoma subtypes.
This work was carried out with the support of an internal grant of Krajská zdravotní, a.s., for the years 2017–2019: IGA217129002.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted: 29. 4. 2019
Accepted: 22. 7. 2019
Keywords:
obesity – overweight – endometrial (endometrioid) adenocarcinoma – czech women – body mass index – odds – endometrial (endometrioid) carcinoma
Zdroje
1. Zdravotnická ročenka České republiky 2017. Praha: ÚZIS 2018: 44.
2. Novotvary 2016. Praha: ÚZIS 2017: 100.
3. Linkos.cz. Česká onkologická společnost ČLS JEP. [online]. Dostupné z: https: //www.linkos.cz/lekar-a-multidisciplinarni-tym/kongresy/po-kongresu/databaze-tuzemskych-onkologickych-konferencnich-abstrakt/epidemiologie-gynekologickych-nadoru/.
4. Kurman RJ (ed). WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer 2014: 222–233.
5. Emons GF, Fleckenstein G, Hinney B et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; (7): 227–242.
6. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; (13): 295–308. doi: 10.1038/modpathol.3880051.
7. Bokhman JV. Two pathogenetics types of endometrial carcinoma. Gynecol Oncol 1983; (15): 10–17.
8. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatosus hyperplasia. Cancer 1985; 56 (6): 1452–1455. doi: 10.1002/1097-0142 (19850915) 56: 6<1452:: aid-cncr2820560637>3.0.co; 2-d.
9. Altekruse SF, Kosary CL, Krapcho M et al. SEER cancer statistic review, 1975–2007. Bethesda: National Cancer Institute 2010.
10. Missaoui NJ, Jaidene L, Abdelkader AB et al. Cancer of corpus uteri in Tunisia: epidemiological and clinicopathological features. Asian Pac J Cancer Prev 2011; 12 (2): 461–464.
11. Parkin DM, Whelan DM, Ferlay J et al (eds.) Cancer incidence in five continents. Lyon: IARC Scientific Publication 1997: 143.
12. Elwood JM, Cole P, Rothman KJ et al. Epidemiology of endometrial cancer. J Natl Cancer Inst 1977; 59 (4): 1055–1060. doi: 10.1093/jnci/59.4.1055.
13. Setiawan VW, Pike MC, Karageorgi S et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol 2012; 176 (4): 269–278. doi: 10.1093/aje/kws129.
14. Nichols HB, Trentham-Dietz A, Hampton JM et al. From menarche to menopause: tends among US women born from 1912 to 1969. Am J Epidemiol 2006; 164 (10): 1003–1011. doi: 10.1093/aje/kwj282.
15. Karageorgi S, Hankinson SE, Kraft P et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976–2004. Int J Cancer 2010; 126 (1): 208–216. doi: 10.1002/ijc.24672.
16. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a syntetic review. Cancer Epidemiol Biomarkers Prev 2002; 11 (12): 1531–1543.
17. Jamison PM, Noone AM, Ries LA et al. Trends in endometrial cancer incidence by race and histology with correlation for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 2013; 22 (2): 233–241. doi: 10.1158/1055-9965.EPI-12-0996.
18. Dossus L, Allen N, Kaaks R et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010; 127 (2): 442–451. doi: 10.1002/ijc.25050.
19. Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 1998; 148 (3): 234–240. doi: 10.1093/oxfordjournals.aje.a009630.
20. Cust AE, Allen NE, Rinaldi S et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 end endometrial cancer risk: results from the Europea Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 120 (12): 2656–2664. doi: 10.1002/ijc.22578.
21. Gao Y, Dai X, Chen L et al. Body mass index is positively associated with endometrial cancer in Chinese women, especially prior to menopause. J Cancer 2016; 7 (9): 1169–1173. doi: 10.7150/jca.15037.
22. Emons G, Fleckenmstein G, Hinney B et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2002; 7 (4): 227–242.
23. Setiawan VW, Yang HP, Pike MC et al. Type I and II endometrial cancers: have they different risc factors? J Clin Oncol 2013; 31 (20): 2607–2618. doi: 10.1200/JCO. 2012.48.2596.
24. Kawachi A, Shimazu T, Budhathoki S et al. Association of BMI and height with the risk of endometrial cancer, overall and histological subtype: a population-based prospective cohort study in Japan. Eur J Cancer Prev 2019; 28 (3): 196–202. doi: 10.1097/CEJ.0000000000000 449.
25. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371 (9612): 569–578. doi: 10.1016/S0140-6736 (08) 60 269-X.
26. Bergström A, Pisani P, Tenet V et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91 (3): 421–430. doi: 10.1002/1097-0215 (200002) 9999: 9999<:: aid-ijc1053>3.0.co; 2-t.
27. Alshahrani S, Soliman AS, Hablas A et al. Change in uterine cancer incidence rates in Egypt. Obstet Gynecol Int 2018; 2018: 3632067. doi: 10.1155/2018/3632 067.
28. Jenabi E Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health 2015; 129 (7): 872–880. doi: 10.1016/j.puhe.2015.04.017.
29. WHO.int. World Health Organization. [online]. Available from: https: //www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
30. World Health Organization Western Pacific Region. International Association for the Study of Obesity, International Obesity Task Force. Redefining obesity and its treatment. Published by Health Communications Australia Pty 2000. [online]. Available from: http: //www.wpro.who.int/nutrition/ documents/docs/Redefiningobesity. pdf.
31. Ortner A, Klammer J, Sattler K. Zur Epidemiologie des Endometriumkarzinoms. Geburtshilfe Frauenheilkd 1980; 40 (7): 624–634. doi: 10.1055/s-2008-1037223.
32. Shu XO, Brinton LA, Zheng W. Relation of obesity and body fat distribution to endometrial cancer in Shanghai, China. Cancer Research 1992; 52 (14): 3865–3870.
33. Swanson CA, Potischman N, Wilbanks GD et al. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomarkers Prev 1993; 2 (4): 321–327.
34. Park SL, Goodman MT, Zhang ZF et al. Body Size, adult BMI gain and endometrial cancer risk: the multiethnic cohort. Int J Cancer 2010; 126 (2): 490–499. doi: 10.1002/ijc.24718.
35. Iatrakis G, Zervoudis S, Saviolakis A et al. Women younger than 50 years with endometrial cancer. Eur J Gynaecol Oncol 2006; 27 (4): 399–400.
36. Lindemann K, Cvancarova M, Eskild A. Body mass index, diabetes and survival after diagnosis of endometrial cancer: a report from the HUNT-survey. Gynecol Oncol 2015; 139 (3): 476–480. doi: 10.1016/j.ygyno.2015.09. 088.
37. Vu M, Seagle B, Abdullah A et al. Body mass index among women with endometrial cancer. Gynecol Oncol 2015; 139 (3): 587. doi: 10.1016/j.ygyno.2015.09.032.
38. Cameselle-Teijeiro JF, Valdés-Pons J, Cameselle-Cortizo L et al. Tumours of the uterine corpus: a histopathological and prognostic evaluation preliminary of 429 patients. J Clin Med Exp Images 2017; 1: 011–019. doi: 10.29328/journal.jcmei.1001004.
39. seer.cancer.gov. SEER Cancer Statistics Review Table 7.11. National Cancer Institute. [online]. Available from: https: //seer.cancer.gov/csr/1975_2015/results_merged/sect_07_ corpus_uteri.pdf#search= uterus.
40. Tichy M, Majdan M, Lastuvka J et al. BMI represents a higher risk of endometrial adenocarcinoma: a cross-sectional study. Abstract S69. In: Malajsian Journal of Nutrition 2015; 21 (Suppl). 9th Asia Pacific Conference on Clinical Nutrition. Malaysia: Kuala Lumpur 2015.
41. MKN-10. Mezinárodní statistická klasifikace nemocí a přidružených zdravotních problémů: desátá revize. Praha: Ústav zdravotnických informací a statistiky ČR 2017.
42. The World Factbook. Central Inteligence Agency. [online]. Available from: https: //www.cia.gov/library/publications/the-world-factbook/rankorder/2127rank.html.
43. Thomas F, Renaud F, Benefice E et al. International variability of ages at menarche and menopause: patterns an main determinants. Hum Biol 2001; 73 (2): 271–290.
44. Evropské výběrové šetření o zdravotním stavu v ČR – EHIS CR. Aktuální informace č. 70/2010. Praha: ÚZIS 2010: 1–11.
45. Weiderpass E, Persson I, Adami HO et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000; 11 (2): 185–192.
46. Tichý M, Ptáčková H, Plančíková D et al. BMI a pravděpodobnost vzniku endometriálního adenokarcinomu u českých žen – případová studie. Klin Onkol 2019; 32 (47): 32 (4): 281–287. doi: 10.14735/amko2019281.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2019 Číslo 4
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Current Perspective on HPV-Associated Oropharyngeal Carcinomas and the Role of p16 as a Surrogate Marker of High-Risk HPV
- Role of the Microbiome in the Formation and Development of Colorectal Cancer
- Oncology Case Report – When Is the Appropriate Time to Integrate Palliative Care?
- Incidence and Risk Factors of Distant Metastases of Head and Neck Carcinoma